OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

8% down today, what a shocker! no, No, NO! we know that OXB has a habit of falling back as short-term punters take their profits - and why not? - let them move on to their next excitement.
However, since there has been "no reason" for the fall we should discount it - the AGM is only weeks away and I suspect we shall ( as in previous years) see some steady improvements towards that time and maybe a further boost as punters phone their brokers on the day,(can't blame the Broker turning a profit?). What happens after that.... is down to market forces, but It will be a Sad day if they reach 38p (as suggested here), for that would be a real "buying op" - so I'd be surprised anyone would wait until it fell below 40p (for example). Am I tempted at these (45-47p) levels? - - No! - - All investments carry risk and whilst I'd be truely gutted by OXB failure, it would be largely a "paper-loss" as they have other products and the likelyhood of multiple failure is almost zero - but it is still possible - for example a terrorist attack, death of several execs as a result of an air-accident...all of these are serious factors.
However, they are rare - - - as indeed are co's with the qualities of OXB - indeed if anyone knows of something similar in both "product potential" and "Execs" - - - leave me a coded-message - I'd willingly take on another Biggie!

It is certainly disappointing that the market is not more positive on the share at the moment.

EVO BUY NOTE TODAY :



OXFORD BIOMEDICA (OXB.L) - BUY - PRICE/TARGET : 41p/61p - MELANOMA VACCINE DATA
Presentation of updated phase II melanoma vaccine data

EVO TAKE - BioMedica's forthcoming presentation of positive phase II results for its melanoma vaccine builds on data previously reported. The trial has produced encouraging signs of efficacy, which in a similar vein to the TroVax results, suggest that the better the immune response the better the clinical response. The Company is optimising the vaccine formulation for even greater efficacy, prior to embarking on another phase II trial. In our view, BioMedica's share price fails to reflect the potential value of TroVax and ascribes no value to promising products such as Hi-8 Mel. Buy.

DETAILS - BioMedica is to present updated phase II results for its therapeutic melanoma vaccine (Hi-8 Mel) at the American Association of Immunologists (AAI) meeting. Recall that Hi-8 Mel, a vaccine for metastatic (advanced) melanoma, was recently added to the pipeline through the 16.3m acquisition of Oxxon Therapeutics. The Company will highlight data from the completed 41-patient phase II trial, which was designed to assess the vaccine's immune and clinical response. The trial has produced signs of efficacy, which in a similar vein to TroVax results, suggest that the better the immune response the better the clinical response:

1. Over 90% of patients receiving the optimal Hi-8 Mel dose generated an immune response to the vaccine.

2. Patients receiving any dose of Hi-8 Mel who developed an immune response specific to one of the vaccine antigens (Melan-A) had a median survival of 100 weeks vs. 37 weeks for immune non-responders (p


3. Tumour responses were seen in 20% of patients as measured by RECIST criteria (a measure of tumour shrinkage) - encouragingly, one patient has shown a partial response (sustained shrinkage) exceeding 12 months.

4. Patients in the control group, who received standard of care, had a median survival of 42 weeks. Median survival for patients receiving Hi-8 Mel was 51 weeks compared to 26 weeks for patients receiving the viral vector component alone (p=0.024).

In terms of next steps, BioMedica is investing the 3m cash acquired with Oxxon to develop Hi-8 Mel up to the start of phase III trials. The viral vector (MVA) used in Hi-8 Mel is the same one used by BioMedica as part of TroVax. The Company's researchers are therefore reconfiguring the vaccine to improve its efficacy. Once achieved, another phase II study will be undertaken prior to embarking on phase III development.

VALUATION AND RECOMMENDATION - Our 61p NPV based target price is currently at a 40% premium to the current share price, which presents a clear buying opportunity. Furthermore, we maintain that the current price only partially reflects the potential value of TroVax (518m deal with Sanofi) and ascribes little or no value to promising products such as Hi-8 Mel. Buy.

Have a look at ASM

16 million shares traded today, must be big holders buying and selling to each other

This is starting to look interesting I may switch some of my ASM into this any thoughts.

I think this is oversold given the recent deal and future prospects. I know that "Jam tomorrow" isn't to everyone's liking but OXB has real prospects and there's the possibility that their jam may be an absolute blockbuster.

Bought in today looks like good support at 37p

Welcome onboard. I hope that OXB proves profitable for you driver.

queen1
I top sliced some ASM its sit and wait time now for both companies.

a couple of charts specially for driver!

as always
red = 25 dma
green = 50 dma
black = 200 dma

cynic
Cheers whats your opinion.

(for Q1's benefit!) ..... I know even less than usual about this company!!

i don't like the way that both 25+50 dma are falling away quite sharply, but i do agree there should be a good chance of a bounce off the 200 dma which is still rising well especially with rsi being less than demanding.

on the way up, obvious resistance would be when sp hits underside of 25 dma at about 44

cynic
Cheers again.

NOTIFICATION OF MAJOR INTERESTS IN SHARES

http://moneyam.uk-wire.com/cgi-bin/articles/200705221553130498X.html

Is it some thing I said up 5%.

at the price you picked that up at driver you should be in profit tomorrow.........

micky468
Already in profit, but it made up for the 2p loss today on ASM but I think it was a good move.

And up we go.

To the top of the hill and